Loading
A phase 3 trial of Iomab-B run by Actinium Pharmaceuticals, active.
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT02665065 by Actinium Pharmaceuticals, with 153 participants enrolled, started 2016-06. Conditions listed: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute. No results are recorded here; the registry entry is the source.
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Actinium Pharmaceuticals, Radio-antibody & radio-ADC, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.